onc Videos

Videos

Videos

Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis

12/19/2022

Francesco Passamonti, MD, presents findings from a study on the combination of navitoclax and ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis at the 2022 ASH Annual Meeting & Exposition.

Francesco Passamonti, MD,...

12/19/2022

Oncology

Videos

Fixed-Duration Ibrutinib Plus Venetoclax Continues to Provide Deep, Durable Responses in CLL

12/16/2022

Ryan Jacobs, MD, discusses 5-year follow-up results from the CAPTIVATE study, which explored long-term outcomes after undetectable MRD with fixed-duration ibrutinib plus venetoclax in patients with CLL.

Ryan Jacobs, MD, discusses...

12/16/2022

Oncology

Videos

Riad Salem, MD, Discusses Data From the PREMIERE and TRACE Clinical Trials in HCC

12/14/2022

Riad Salem, MD, discusses data from 2 clinical trials comparing Y90 radioembolization vs conventional transarterial chemoembolization and drug-eluting bead transarterial chemoembolization for patients with HCC.

Riad Salem, MD, discusses data...

12/14/2022

Oncology

Videos

Sorafenib Added to CLAG-M Produces High Rates of Complete Remission With MRD Negativity in AML and Myeloid Neoplasms

12/14/2022

Anna Halpern, MD, presents study findings showing the addition of sorafenib to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone (CLAG-M) produces high rates of complete remission with MRD negativity in newly diagnosed AML and...

Anna Halpern, MD, presents study...

12/14/2022

Oncology

Leena Gandhi, MD, PhD, Dana-Farber Cancer Institute

Videos

How to Handle Patients With PD-L1 >50% Non-Small Cell Lung Cancer

12/13/2022

Leena Gandhi, MD, PhD, discusses the debate held at the 2022 Great Debates and Updates in Lung Cancer meeting, addressing first-line treatment options for patients with non-small cell lung cancer and PD-L1 > 50%.

Leena Gandhi, MD, PhD, discusses...

12/13/2022

Oncology

Mark Awad, MD, PhD, Dana-Farber Cancer Institute

Videos

Overcoming Resistance to Checkpoint Inhibitors in Lung Cancer

12/13/2022

Dr Mark Awad reviews his presentation at the 2022 Great Debates and Updates in Lung Cancer meeting in New York which focused on the management of patient resistance to checkpoint inhibitors.

Dr Mark Awad reviews his...

12/13/2022

Oncology

Videos

BTK Inhibitor Class Switching in the First-Line Treatment of CLL and SLL: Real-World Outcomes

12/13/2022

Ryan Jacobs, MD, discusses findings from a real-world analysis exploring BTK inhibitor-class switching in the first-line treatment of CLL and SLL, suggesting approximately 40% of patients who switch from ibrutinib to acalabrutinib experience...

Ryan Jacobs, MD, discusses...

12/13/2022

Oncology

Videos

Efficacy and Safety of Parsaclisib Add-on to Ruxolitinib in Patients With Myelofibrosis

12/12/2022

At the 2022 ASH Annual Meeting and Exposition, Abdulraheem Yacoub, MD, presented final results from a phase 2 study on the efficacy and safety of adding parsaclisib to ruxolitinib therapy in patients with myelofibrosis.

At the 2022 ASH Annual Meeting...

12/12/2022

Oncology

Videos

Talquetamab Demonstrates Robust Efficacy, Manageable Safety in Patients With Heavily Pretreated R/R Multiple Myeloma

12/12/2022

At the 2022 ASH Annual Meeting and Exposition in New Orleans, LA, Ajai Chari, MD, discusses talquetamab efficacy and safety for patients with heavily pretreated relapsed/refractory multiple myeloma.

At the 2022 ASH Annual Meeting...

12/12/2022

Oncology

Aditya Bardia, MD, MPH, Mass General Cancer Center

Videos

Sacituzumab Govitecan Improves Survival Regardless of Trop-2 Expression Status for HR+, HER− Breast Cancer

12/09/2022

At the 2022 San Antonio Breast Cancer Symposium, Aditya Bardia, MD, MPH, shared results from the phase 3 TROPiCS-02 trial investigating sacituzumab govitecan vs physician choice of chemotherapy in previously treated patients with HR+/HER2−...

At the 2022 San Antonio Breast...

12/09/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology